Home › Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia clinical trials recruiting in the U.S.
42 studies for Chronic Myelomonocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX16 studies
- Seattle, WA10 studies
- Boston, MA7 studies
- Baldwin Park, CA6 studies
- Mountain View, CA6 studies
- New York City, NY6 studies
- Rochester, MN6 studies
- Durham, NC5 studies
- Birmingham, AL4 studies
- Miami, FL4 studies
- Atlanta, GA4 studies
- Tampa, FL4 studies
- Columbus, OH4 studies
- Portland, OR3 studies
- Los Angeles, CA3 studies
- Charleston, SC3 studies
- Nashville, TN3 studies
By state
- Alabama4 studies
- California12 studies
- Florida8 studies
- Georgia4 studies
- Maryland3 studies
- Massachusetts7 studies
- Minnesota7 studies
- New York8 studies
- North Carolina5 studies
- Ohio5 studies
- Oregon3 studies
- Pennsylvania4 studies
- South Carolina3 studies
- Tennessee3 studies
- Texas18 studies
- Washington10 studies
Recently updated studies
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06904066Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06523556Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
RecruitingPhase 2/3Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 11, 2026 · NCT04708054Pacritinib in CMML
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06159491Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RecruitingPhase 1/2
Ages 12 to 80 · All sexes · Updated Aug 7, 2026 · NCT05092451Personalized NK Cell Therapy in CBT
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Jul 30, 2026 · NCT02727803Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT07046078Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT07128381Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 29, 2026 · NCT06815003211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT05549661Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RecruitingEarly phase 1
Ages 18 to 75 · All sexes · Updated Jun 3, 2026 · NCT03964506Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.